Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5070872 | 1.00 | PDK2 (0.32) | PDK2GABRA1GABRB1GABRG2GABRB3 | |
| SCHEMBL5069210 | 0.80 | TSHR (0.37) | PDK2ALDH1A1HPGDTSHR | |
| SCHEMBL5069211 | 0.80 | TSHR (0.37) | PDK2ALDH1A1HPGDTSHR | |
| SCHEMBL5069206 | 0.79 | GABRA1 (0.38) | GABRA1GABRB1GABRG2GABRB3GABRB2 | |
| SCHEMBL5069207 | 0.79 | GABRA1 (0.38) | GABRA1GABRB1GABRG2GABRB3GABRB2 | |
| SCHEMBL5070895 | 0.67 | GABRA1 (0.35) | GABRA1GABRB1GABRG2GABRB3GABRB2 | |
| SCHEMBL5070893 | 0.67 | GABRA1 (0.35) | GABRA1GABRB1GABRG2GABRB3GABRB2 | |
| SCHEMBL8765133 | 0.66 | MEN1 (0.40) | ALDH1A1TSHR | |
| SCHEMBL8765130 | 0.66 | MEN1 (0.40) | ALDH1A1TSHR | |
| SCHEMBL7278658 | 0.65 | KMT2A (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5136080-A | Intermediates for glutamate inhibitors | BURROUGHS WELLCOME CO. (US) | 1992-08-04 | — | — | US | claimed |
| EP-1325916-B1 | Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system | WELLCOME FOUND (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-0727213-B9 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | WELLCOME FOUND (GB) | 2007-11-07 | — | — | EP | disclosed |
| EP-1681058-A2 | Pharmacologically active cns compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 2006-07-19 | — | — | EP | disclosed |
| EP-0727213-B1 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | WELLCOME FOUND (GB) | 2005-10-26 | — | — | EP | disclosed |
| EP-1325916-A1 | Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system | THE WELLCOME FOUNDATION LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| US-5712276-A | TREATING NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME INC. (US) | 1998-01-27 | — | — | US | disclosed |
| US-5684005-A | PHENYLPYRIMIDINE COMPOUNDS AS INHIBITORS OF EXCITATORY AMINO ACID GLUTAMATE | GLAXO WELLCOME INC. (US) | 1997-11-04 | — | — | US | disclosed |
| US-5635507-A | PIPERAZINYL PHENYLPYRIMIDINE COMPOUND TREATING BRAIN DISORDER | GLAXO WELLCOME INC. (US) | 1997-06-03 | — | — | US | disclosed |
| US-5597827-A | CENTRAL NERVOUS SYSTEM DISORDERS AND ANTIISCHEMIC AGENTS | GLAXO WELLCOME INC. | 1997-01-28 | — | — | US | disclosed |
| US-5587380-A | ANTIISCHEMIC AGENTS | GLAXO WELLCOME INC. (US) | 1996-12-24 | — | — | US | disclosed |
| EP-0727213-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| EP-0727214-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| EP-0727212-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| EP-0715851-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-12 | — | — | EP | disclosed |
| EP-0713703-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-29 | — | — | EP | disclosed |
| EP-0679645-A1 | Pharmacologically active CNS pyridmidin compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-11-02 | — | — | EP | disclosed |
| US-5136080-A | Intermediates for glutamate inhibitors | BURROUGHS WELLCOME CO. (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0459819-A2 | Pharmacologically active CNS compound | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-12-04 | — | — | EP | disclosed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | disclosed |